ライフサイエンスコーパス: immunotoxin

1 e potency curve on the basis of internalized immunotoxin.

2 from humans who had been treated with ricin immunotoxin.

3 , we depleted CD4+CD25+ T cells with an IL-2 immunotoxin.

4 ncluding saline, naked hLL1, and nonspecific immunotoxin.

5 tumomab pasudotox is a recombinant anti-CD22 immunotoxin.

6 splant allografts ex vivo using an anti-CD25 immunotoxin.

7 he infected cells susceptible to an anti-HIV immunotoxin.

8 ry MLR were first depleted with an anti-CD25 immunotoxin.

9 splenectomy, rituximab (mabthera), and BL-22 immunotoxin.

10 ainst aggregation compared with the starting immunotoxin.

11 22 antibodies or our highly potent anti-CD22 immunotoxin.

12 and protein, and were sensitive to our CD22 immunotoxin.

13 monoclonal antibodies, immunoconjugates, and immunotoxins.

14 ized to improve the potency of gelonin-based immunotoxins.

15 n by antibodies, immunoconjugates, and other immunotoxins.

16 ted by evaluating the anticancer efficacy of immunotoxins.

17 ancer therapy that employs saporin-L1-linked immunotoxins.

18 ach that may be applicable to other PE-based immunotoxins.

19 e in mediating the toxicity of anti-EGFRvIII immunotoxins.

20 t of Pseudomonas exotoxin A (PE38) to create immunotoxins.

21 at these cells cannot be killed by anti-CD22 immunotoxins.

22 gents were not cross-resistant to rGel-based immunotoxins.

23 el and promising therapeutic approaches like immunotoxins.

24 uced by bilaterally infusing the cholinergic immunotoxin 192 IgG-saporin into the NBM.

25 Rats received PBS or the immunotoxin 192IgG-saporin (192Sap) intracerebroventricu

26 describe high antitumor activity of a novel immunotoxin, 2L-Rap-hLL1-gamma4P, composed of 2 Rap mole

27 in vivo studies showed that an anti-RPTPbeta immunotoxin (7E4B11-SAP) could significantly delay human

28 of dorsal horn microglia with the Mac-1-SAP immunotoxin, a chemical conjugate of mouse monoclonal an

29 pies currently in clinical trials include an immunotoxin, a chimeric monoclonal antibody, and an anti

30 ts suggest that, rather than using toxins or immunotoxins, a more biological approach to decrease mus

31 We demonstrated that algal-produced immunotoxins accumulate as soluble and enzymatically act

32 at the insulin receptor negatively regulates immunotoxin action.

33 yclonal or monoclonal antibodies, the use of immunotoxins, additional immunosuppressive/chemotherapeu

34 ent neurotoxicity associated with CRM9-based immunotoxin administration in swine.

35 Immunotoxins against both antigens have been evaluated,

36 n synthesis, we show for the first time that immunotoxins also reduce the levels of selected proapopt

37 y MHC-mismatched TK transplants treated with immunotoxin and a 12-day course of CsA accepted their co

38 unologically tolerant macaques, induced with immunotoxin and deoxyspergualin, developed neither acute

39 ipients were treated with a T-cell-depleting immunotoxin and received fully MHC-mismatched TK grafts

40 Such molecules, termed immunotoxins and antibody-drug conjugates, respectively,

41 major and often dose-limiting side effect of immunotoxins and cytokines.

42 The anti-CD105 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppres

43 ld facilitate the development of more active immunotoxins and other antibody based agents.

44 nish the nonspecific toxicity of recombinant immunotoxins and other Fv fusion proteins without losing

45 22 a better therapeutic target than CD19 for immunotoxins and probably for other immunoconjugates tha

46 oning consisted of T cell depletion with CD3-immunotoxin, and 100 cGy total body irradiation prior to

47 sing number of active monoclonal antibodies, immunotoxins, and radioimmunoconjugates (RICs) has stimu

48 ll as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examin

49 roaches, including antibody-drug conjugates, immunotoxins, and targeted nucleic acid delivery, requir

50 newly developed anti-monkey CD3 recombinant immunotoxin (anti-CD3 rIT) and an anti-human CD2 antibod

51 Immunotoxins (antibody-toxin fusion proteins) target sur

52 on of the axonally transported catecholamine immunotoxin, antiDBH-saporin.

53 f split PE3 offers a direct extension of the immunotoxin approach to generate bispecific agents that

54 cology therapeutics, with eight ADCs and two immunotoxins approved for clinical use.

55 Anti-CD3 immunotoxins are broad-spectrum immunosuppressive agents

56 Individual immunotoxins are designed to treat specific cancers.

57 Recombinant immunotoxins are genetically engineered proteins in whic

58 cate that ABD-containing deimmunized HN3-T20 immunotoxins are high-potency therapeutics ready to be e

59 Recombinant immunotoxins are hybrid proteins composed of an Fv that

60 Both internalized immunotoxins are located in the same vesicles.

61 The most potent immunotoxins are made from bacterial and plant toxins.

62 Immunotoxins are one such targeted therapeutic, consisti

63 Immunotoxins are proteins used to treat cancer that are

64 or CD20 and bound to different cytotoxins or immunotoxins are under development.

65 Such compounds, termed immunotoxins, are delivered to the interior of leukemia

66 In detail, we synthesized a novel modular immunotoxin B3(dsFv)-PE38 (B3-PE38) in which the antibod

67 ng revealed the highest cytotoxicity for the immunotoxin B3-PE38 in the 2D model.

68 We compared the efficacy of the immunotoxin B3-PE38, the toxin E8C-PE38 (PE38) and the s

69 Interestingly, the immunotoxin based on HN3 (HN3-PE38) has superior antitum

70 Immunotoxins based on Pseudomonas exotoxin A (PE) are pr

71 use in tumor therapy, we have generated the immunotoxins based on the Fv of these antibodies.

72 shes glypican-3 as a promising candidate for immunotoxin-based liver cancer therapy.

73 The immunotoxin binds to a surface antigen on a cancer cell,

74 nd (3) GPC3-specific therapeutics, including immunotoxin, bispecific antibody and chimeric antigen re

75 Immunotoxin BL22 targets CD22 positive malignancies and

76 Recombinant immunotoxin BL22, containing the Fv portion of an anti-C

77 he cytotoxicity of the anti-CD22 recombinant immunotoxin BL22.

78 Both immunotoxins bound to FCRL1-positive cells with similar

79 an 75% of the cytotoxicity of 1,000 ng/mL of immunotoxin, but this immunogenicity was rare (5%) after

80 were treated with CsA alone or both CsA and immunotoxin, but with a normal kidney or a kidney implan

81 region of V(H) increased the potency of the immunotoxin by approximately 10-fold in a cell-killing a

82 el strategy to increase tumor cell uptake of immunotoxin by combination with Taxol.

83 fficacy, we have produced a less immunogenic immunotoxin by identifying and eliminating most of the B

84 pursued a strategy to deimmunize recombinant immunotoxins by identifying and removing B-cell epitopes

85 A single intraocular injection of the immunotoxin caused a rapid, complete, and selective loss

86 ican-3 (GPC3)-targeting human nanobody (HN3) immunotoxins causes potent tumor regression by blocking

87 A single dose of the immunotoxin, CD45-saporin (SAP), enabled efficient (>90%

88 proteins in the response of cancer cells to immunotoxin challenge.

89 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28,

90 HA22 is a recombinant immunotoxin composed of an anti-CD22 Fv fused to a porti

91 SS1P is a recombinant immunotoxin composed of an antimesothelin Fv fragment fu

92 LMB-2 (anti-Tac(Fv)-PE38) is a recombinant immunotoxin composed of the Fv fragment of the anti-Tac

93 SS1P is an immunotoxin composed of the Fv portion of a mesothelin-s

94 Recombinant immunotoxins composed of an Ab Fv fragment joined to a t

95 cytokine, we examined whether a recombinant immunotoxin comprised of human IL-13 and a mutated form

96 A recombinant immunotoxin, comprising exotoxin A domain III (PE-III) f

97 ression, trafficking kinetics, extracellular immunotoxin concentration, and exposure time were all fo

98 ing MUC1-expressing cells directly and as an immunotoxin conjugate.

99 Here we show that an immunotoxin consisting of an anti-PD-1 single-chain vari

100 This ipRGC immunotoxin, consisting of saporin conjugated to a melan

101 graft model, we describe the synthesis of an immunotoxin, consisting of the F(ab')2 fragment of a mon

102 as to characterize a series of anti-Her2/neu immunotoxin constructs to identify how different antibod

103 RFB4(dsFv)-PE38 (BL22), a recombinant immunotoxin containing an anti-CD22 variable domain (Fv)

104 We constructed a series of immunotoxins containing either the human single-chain an

105 the affinity and cytotoxicity of recombinant immunotoxins containing mouse single-chain variable regi

106 ability of an antibody to make an effective immunotoxin could not be predicted from its other functi

107 Anti-HIV immunotoxins could be used to eliminate virus reservoirs

108 In addition, these immunotoxins could upregulate the cellular expression of

109 this region using HA22, an anti-CD22 Fv-PE38 immunotoxin currently undergoing clinical trials for B-c

110 We demonstrated that a CD25(high) targeting immunotoxin (denileukin diftitox) depleted FoxP3(+) Treg

111 This anti-I-A(k) gelonin immunotoxin depletes I-A(k) expressing cells specificall

112 ells in the developing ferret retina through immunotoxin depletion of starburst amacrine cells.

113 the JAK inhibitor) quells Ab responses to an immunotoxin derived from the bacterial protein Pseudomon

114 Immunotoxins derived from Pseudomonas exotoxin are antib

115 RG7787 is a mesothelin-targeted immunotoxin designed to have low-immunogenicity, high-cy

116 We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is s

117 ete the graft of alloreactive cells using an immunotoxin directed against the activation marker CD25.

118 l proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells

119 All of our immunotoxins displayed high affinity to human GPC3, with

120 Systemic administration of these immunotoxins dose-dependently depleted >99% of tg(epsilo

121 Three anti-human CD3-directed immunotoxins, DT389-scFv(UCHT1), scFv(UCHT1)-PE38, and U

122 st T-cell antigens (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox).

123 Two recombinant immunotoxins, E3(Fv)-PE38 and E9(Fv)-PE38, were construc

124 Our results suggest that anti-FCRL1 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cyt

125 The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu ex

126 that lysosomal protease digestion may limit immunotoxin efficacy unless the susceptible domain is el

127 More strikingly, the immunotoxin efficacy was substantially higher in the 3D

128 ough specific, proteolytic cleavage with the immunotoxin EGF-SubA represents a novel and promising mu

129 All three immunotoxins elicited >100 day median survival of fully

130 Immunotoxins exhibited K(d) values between 8 and 15 nm a

131 ning of therapeutic targets, we compared two immunotoxins, FMC63(Fv)-PE38-targeting CD19 and RFB4(Fv)

132 nstrate that allodepletion with an anti-CD25 immunotoxin following stimulation with HLA-mismatched ho

133 hat we have developed a specific cholinergic immunotoxin for mice.

134 These have been evaluated alone and as immunotoxins for activity, ability to induce pulmonary v

135 The use of immunotoxins for cancer therapy is an attractive strateg

136 directed mutants may increase the utility of immunotoxins for reducing or eradicating persistent HIV-

137 vity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the

138 A single intravitreal injection of immunotoxin HA22 after the establishment of the PIOL res

139 The therapeutic effectiveness of immunotoxin HA22 was tested by injecting the drug intrav

140 A recombinant immunotoxin (HA22, CAT8015, moxetumomab pasudotox) compo

141 The new immunotoxin (HA22-8X) is significantly less immunogenic

142 , we eliminated these epitopes to produce an immunotoxin (HA22-LR-8M) that is fully cytotoxic against

143 pitope information, we constructed a variant immunotoxin, HA22-LR-LO10, which has low reactivity with

144 The new immunotoxin has a 93% decrease in T-cell epitopes and sh

145 Recombinant immunotoxins have been shown to be highly cytotoxic to l

146 o our previously reported B-cell deimmunized immunotoxin (HN3-mPE24) and our original HN3-immunotoxin

147 ether inhibiting systemic Tregs with an IL-2 immunotoxin in a model of neu-mediated breast cancer, th

148 ic activity when compared with the wild-type immunotoxin in an adenosine diphosphate-ribosylation ass

149 Treatment with the immunotoxin in conjunction with agents that activate vir

150 To trace the in vivo pharmacokinetics of the immunotoxin in mice, we labeled the antiTac(Fv)-PE38 wit

151 For the detection of immunotoxin in mouse serum, we developed a highly sensit

152 of T-cell-depleting antibodies, such as CD3 immunotoxin in primates and CAMPATH-1H in humans, has de

153 utic agents and synergized with an anti-CD22 immunotoxin in vitro.

154 -infected cells are selectively killed by an immunotoxin in which a truncated form of Pseudomonas exo

155 portant clinical implications for the use of immunotoxins in the therapy of patients with cancer.

156 and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5.

157 Mechanistic studies showed that both immunotoxins induced melanoma cell necrosis.

158 Furthermore, immunotoxin-induced lesions of medial septal neurons, pr

159 Our results demonstrate immunotoxin-induced tumour regression via dual mechanism

160 Immunotoxin injections in the dorsal mPFC (centered in t

161 -CCR4 immunotoxin, two doses of an anti-CD25 immunotoxin (interleukin-2 with diphtheria toxin [IL-2-D

162 ar reservoir of CD22 decreases greatly after immunotoxin internalization, indicating that it contribu

163 The intoxication pathway of PE immunotoxins involves receptor-mediated internalization

164 The hSGZ immunotoxin is a highly potent and selective agent that

165 particles, suggesting that this recombinant immunotoxin is a promising molecular template in drug di

166 RG7787 (anti-mesothelin recombinant immunotoxin) is highly cytotoxic to pancreatic cancer ce

167 An anti-CD45RO immunotoxin (IT) can decrease the number of both product

168 we demonstrate that depletion using anti-CD3 immunotoxin (IT) combined with maintenance immunosuppres

169 The potential benefit of immunotoxin (IT) for cancer therapy has mostly been limi

170 + cells displayed relative resistance to the immunotoxin (IT) HuM195-gelonin and to free rGelonin.

171 m-cell transplants (SCTs) using an anti-CD25 immunotoxin (IT) is a strategy to prevent acute graft-ve

172 Immunotoxin (IT) therapy shows potential for selectively

173 nert (NBM) were selectively lesioned with an immunotoxin (IT), 192 IgG-saporin.

174 Anti-CD3 immunotoxin (IT), a T-cell-depleting agent, prolongs sur

175 ng the HIV-producing cells with an anti-CD25 immunotoxin (IT).

176 Immunotoxins (ITs) targeting the HIV envelope protein ar

177 is possibility, we generated two recombinant immunotoxins (ITs) using the single-chain Fv (scFv) of M

178 In the macaques, we tested immunotoxins (ITs), consisting of protein toxins bound t

179 Immunotoxins (ITs), which consist of antibodies conjugat

180 ms or as cytotoxic immunoconjugates, such as immunotoxins (ITs).

181 or chemical intervention that could increase immunotoxin killing of cancer cells and enhance our unde

182 r, the p97 inhibitor eeyarestatin 1 enhanced immunotoxin killing.

183 In immunotoxin (LMB2) induced fatal podocyte injury (NEP25/

184 This novel immunotoxin may be useful in the treatment of strabismus

185 This novel immunotoxin may be useful in the treatment of strabismus

186 rm of the immune system using agents such as immunotoxins may be a useful adjuvant to existing recipi

187 Site-specific PEGylation of recombinant immunotoxins may increase their therapeutic potency in h

188 rupted by making bilateral injections of the immunotoxin ME20.4-SAP into the NB.

189 cortex infusions of a selective cholinergic immunotoxin, ME20.4-SAP, with the performance of monkeys

190 onsisting of 100 cGy total body irradiation, immunotoxin mediated T-cell depletion, and a short cours

191 Finally, selective immunotoxin-mediated ablation of GABAergic aBST neurons

192 ied that a Bim knockout completely abolished immunotoxin-mediated apoptosis.

193 expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the tr

194 otuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-

195 We used the murine-p75-saporin immunotoxin (mu-p75-sap) to induce selective lesions of

196 ived CD3 T-lymphocyte depletion therapy with immunotoxin on the day of the transplantation (n=7) or 7

197 the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines.

198 ul as a tumor marker, a target for cytotoxin/immunotoxin, or alternatively, a tumor-associated antige

199 Immunotoxin orientation can significantly impact the ove

200 were given intraventricular infusions of the immunotoxin OX7-saporin to selectively destroy Purkinje

201 cted, silencing known essential genes in the immunotoxin pathway, such as mesothelin, furin, KDEL rec

202 on in miniature swine using a CRM9-based CD3-immunotoxin, pCD3-CRM9.

203 These immunotoxins profoundly deplete T cells in vivo and effe

204 into 3 groups based on their effector type: immunotoxins (protein toxin), radioimmunoconjugates (rad

205 on and accumulation of monomeric and dimeric immunotoxin proteins in algal chloroplasts.

206 dings suggest that the newly developed ipRGC immunotoxin provides a potent method for achieving relat

207 Administration of pCD3-CRM9 immunotoxin provides excellent T-cell depletion in minia

208 ng cell surface receptors with cytotoxins or immunotoxins provides a unique opportunity for tumor the

209 In all mouse models, the immunotoxin reduced the numbers of PD-1-expressing cells

210 on of the WDR85 gene could be a mechanism of immunotoxin resistance in patients undergoing immunotoxi

211 Our data show that immunotoxin resistance is associated with reversible CpG

212 usceptibility to recombinant IL-13 and IL-13 immunotoxin, respectively.

213 tulinum toxin type A and, more recently, the immunotoxin ricin-mAb35 have been effective as means of

214 The immunotoxin, ricin-mAb 35, composed of ricin conjugated

215 Recombinant immunotoxin (RIT) therapy is limited in patients by neut

216 Recombinant immunotoxins (RIT) have been highly successful in cancer

217 Recombinant immunotoxins (RITs) are chimeric proteins composed of an

218 Recombinant immunotoxins (RITs) are chimeric proteins designed to tr

219 Recombinant immunotoxins (RITs) are chimeric proteins that are being

220 Recombinant immunotoxins (RITs) are hybrid proteins used to treat ca

221 Recombinant immunotoxins (RITs) are potent anticancer agents that ha

222 using the axonally transported catecholamine immunotoxin, saporin-conjugated antiserum to dopamine-be

223 observation that many RNAi targets increased immunotoxin sensitivity, indicating that these gene prod

224 r refractory Hodgkin lymphoma, including the immunotoxin SGN-35 and the histone deacetylase inhibitor

225 In vivo targeting studies with an anti-CDCP1 immunotoxin showed significant inhibition of primary tum

226 mpared with unmodified LMB-2, both PEGylated immunotoxins showed similar cytotoxic activities in vitr

227 t treatment with either the mono- or dimeric immunotoxins significantly prolongs the survival of mice

228 on of human PBMC with LMB-2, a CD25-directed immunotoxin, significantly reduced CD25+ FOXP3+ CD4+ Tre

229 An immunotoxin specific for human lens epithelial cells sho

230 bsequently, mutations were made in two other immunotoxins, SS1(dsFv)-PE38 targeting ovarian cancer an

231 not compete for mesothelin binding with the immunotoxin SS1P that binds Region I of mesothelin.

232 cantly improved the in vitro cytotoxicity of immunotoxin SS1P, which targets mesothelin and is curren

233 the cytotoxicity of the mesothelin-directed immunotoxin SS1P.

234 These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesoth

235 the framework region of the Fv portion of an immunotoxin targeting CD25 [anti-Tac(scFv)-PE38] lowered

236 titate tumor cell uptake of Herceptin and an immunotoxin targeting HER2/neu.

237 herapeutic potential of a recently developed immunotoxin targeting human B-cell lymphomas.

238 We have recently reported that an immunotoxin targeting mesothelin produced durable major

239 Here we report an internalizing immunotoxin targeting the hematopoietic-cell-restricted

240 t both antigens have been evaluated, and the immunotoxins targeting CD22 are more active.

241 Clinical studies with immunotoxins targeting CD25 and CD22 have shown that dos

242 responses have been observed in trials with immunotoxins targeting solid tumors, because only a sing

243 ytolethal distending toxin (Cdt) is a potent immunotoxin that induces G(2) arrest in human lymphocyte

244 HA22 is a recombinant immunotoxin that kills CD22-expressing cells by ADP-ribo

245 escribe the development and validation of an immunotoxin that specifically targets the ipRGC populati

246 This was true for two doses of immunotoxin; the greater compensation occurring with the

247 ategies improve the efficacy of antibody and immunotoxin therapies but have not yet been thoroughly e

248 Immunotoxin therapy is very effective in hairy cell leuk

249 The results of B cell-specific immunotoxin therapy may have clinical implications in tr

250 mmunotoxin resistance in patients undergoing immunotoxin therapy.

251 ts over many years have produced recombinant immunotoxins; these therapeutic proteins are made using

252 We have used an anti-CD25 immunotoxin to deplete alloreactive lymphocytes and have

253 on protocol combined peritransplant anti-CD3 immunotoxin to deplete T-cells and 15-deoxyspergualin to

254 similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes

255 Administration of anti-SR-A immunotoxin to mice challenged with peritoneal ID8 tumor

256 Administration of the immunotoxin to mouse models of autoimmune diabetes delay

257 demonstrate the capacity of a CD25-directed immunotoxin to selectively mediate a transient partial r

258 d peripheral blood mononuclear cells with an immunotoxin to stimulate T-cell expansion, followed by e

259 ress these concerns, we engineered HN3-based immunotoxins to contain various deimmunized Pseudomonas

260 rotein levels correlated with the ability of immunotoxins to induce an apoptotic response.

261 gated the proteolytic susceptibility of PE38 immunotoxins to lysosomal proteases and found that cleav

262 ort serum half-life may limit the ability of immunotoxins to transition to the clinic.

263 induced, splenic proliferative response from immunotoxin-treated animals further demonstrated specifi

264 Using sera from immunotoxin-treated patients, the formation of human Abs

265 Immunotoxin-treated rhesus monkeys emerge as an outstand

266 clinically, we analyzed patient cells before immunotoxin treatment and report that samples of hairy c

267 Immunotoxin treatment prolonged fully allogeneic skin gr

268 ild-type or Bid knockout tumors responded to immunotoxin treatment with a decrease in growth kinetics

269 ial biomarker that could be evaluated before immunotoxin treatment.

270 ete abrogation of the therapeutic effects of immunotoxin treatment.

271 r size or prolongation of survival following immunotoxin treatment.

272 gnificantly more sensitive than monocytes to immunotoxins treatment.

273 iation, and we depleted their T-cells by CD3 immunotoxin-treatment.

274 t strategies: administration of an anti-CCR4 immunotoxin, two doses of an anti-CD25 immunotoxin (inte

275 cluding monoclonal antibodies, ligand-linked immunotoxins, tyrosine kinase inhibitors, and antisense

276 hrough endosomes/lysosomes, during which the immunotoxin undergoes important proteolytic processing s

277 her cytotoxic drug as a strategy to increase immunotoxin uptake by tumor cells.

278 However, the anti-CD3 immunotoxins used in animal studies do not cross-react w

279 ion IT targeted to gp120, CD4-PE40 (chimeric immunotoxin using CD4 and the translocation and enzymati

280 We have synthesized novel gelonin immunotoxins using two different binding scaffold types

281 Gelonin-based immunotoxins vary widely in their cytotoxic potency as a

282 gelonin (via pinocytosis) and gelonin-based immunotoxins (via antigen-dependent, receptor-mediated e

283 hypothesis directly, a new cholinergic cell immunotoxin was constructed by conjugating saporin, the

284 SS1P, a Pseudomonas exotoxin-based immunotoxin, was chosen because it is now in clinical tr

285 r leak at the same dose and, when used as an immunotoxin, was more effective in xenografted SCID mice

286 SS1P, an anti-mesothelin immunotoxin, was the first mesothelin-directed therapy t

287 Hippocampal ChAT depletions induced by the immunotoxin were consistently greater than neocortical d

288 These immunotoxins were extraordinarily potent in vitro agains

289 The immunotoxin, which leads to selective cholinergic deaffe

290 mmune response to the toxin component of the immunotoxin, which limits the number of cycles that can

291 cells sensitive to killing by an anti-HIV-1 immunotoxin while minimizing the side effects of CD4 and

292 with rituximab, bendamustine, and conjugate immunotoxins will reveal what role these therapies will

293 immunotoxin (HN3-mPE24) and our original HN3-immunotoxin with a wild-type PE domain (HN3-PE38).

294 BL22, an immunotoxin with impressive activity in hairy cell leuke

295 Injection of anti-Tac (Fv)-PE38 (LMB2), an immunotoxin with specific binding to human CD25, induced

296 asparagine 31 with arginine produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold

297 lts provide a strong rationale for combining immunotoxins with cancer vaccines for the treatment of p

298 that antibodies with increased affinity and immunotoxins with increased activity could be obtained b

299 Because the immunotoxin works only when it is internalized and becau

300 One immunotoxin (YP218 Fv-PE38) exhibits potent anti-tumor c